23andMe teams up with Genentech on Parkinson's genomics
This article was originally published in Clinica
Executive Summary
Personal genetics firm 23andMe is teaming up with pharma company Genentech, a Roche subsidiary, to analyze the genomes of Parkinson's disease patients in the hope of finding new drug targets.
You may also be interested in...
UK Has ‘Much Room For Improvement’ On Genomic Testing Access
UK patient outcomes would improve under clearer, standardized market access or reimbursement pathways for advanced diagnostic tests, such as those used to screen for cancer, trade groups say.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.